Rider J.R., Wilson K.M., Sinnott J.A. et al. Ejaculation frequency and risk of prostate cancer: updated results with an additional decade of follow-up. Eur Urol 2016;70(6):974–82.
DOI: 10.1016/j.eururo.2016.03.027
Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под. ред. А.Д. Каприна, В.В. Старинского, Г.В. Петрова. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.
Аляев Ю.Г., Асламазов Э.Г., Ахвледиани Н.Д. 145 лет урологической клинике имени Р.М. Фронштейна. М.: Дипак, 2012. 240 с.
Huggins C., Hodges C.V. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phos phatases in metastatic carcinoma of the prostate. Cancer Res 1941;1(4):293–7.
Huggins C., Stevens R.E., Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43(2):209–23.
DOI: 10.1001/archsurg.1941.01210140043004
Morgentaler A., Traish A. The history of testosterone and the evolution of its therapeutic potential. Sex Med Rev 2020;8(2):286–96.
DOI: 10.1016/j.sxmr.2018.03.002
Prout G.R. Jr., Brewer W.R. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967;20(11):1871–8.
DOI: 10.1002/1097-0142(196711)20:113.0.co;2-d
Fowler J.E. Jr., Whitmore W.F. Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126(3):372–5.
DOI: 10.1016/s0022-5347(17)54531-0
Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16.
DOI: 10.1056/nejm198710083171501
Morgentaler A., Bruning C.O. 3rd, DeWolf W.C. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276(23):1904–6.
DOI: 0.1001/jama.1996.03540230054035
Morgentaler A., Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006;68(6):1263–7.
DOI: 10.1016/j.urology.2006.08.1058
Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350(5):482–92.
DOI: 10.1056/NEJMra022251
Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam A.W., Allen N.E., Appleby P., Key T.J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100(3):170–83.
DOI: 10.1093/jnci/djm323.
Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50(5):935–9.
DOI: 10.1016/j.eururo.2006.06.034
Morgentaler A., Traish A.M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55(2):310–20.
DOI: 10.1016/j.eururo.2008.09.024
Wright A.S., Douglas R.C., Thomas L.N. et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alphareductase. Endocrinology 1999;140(10):4509–15.
DOI: 10.1210/endo.140.10.7039
Traish A.M., Muller R.E., Wotiz H.H. A new procedure for the quantitation of nuclear and cytoplasmic androgen receptors. J Biol Chem 1981;256(23):12028–33.
Traish A.M., Williams D.F., Hoffman N.D., Wotiz H.H. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res 1988;262:145–60.
Marks L.S., Mazer N.A., Mostaghel E. et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296(19):2351–61.
DOI: 10.1001/jama.296.19.2351
Salonia A., Abdollah F., Capitanio U. et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res 2012;18(13):3648–57.
DOI: 10.1158/1078-0432.CCR-11-2799
Miranda E.P., Torres L.O. Late-onset hypogonadism: prostate safety. Andrology 2020;8(6):1606–13.
DOI: 10.1111/andr.12772
Debruyne F.M., Behre H.M., Roehrborn C.G. et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int 2017;119(2):216–24.
DOI: 10.1111/bju.13578
Elliott J., Kelly S.E., Millar A.C. et al. Testosterone therapy in hypogonadal men: a systematic review and network metaanalysis. BMJ Open 2017;7(11):e015284.
DOI: 10.1136/bmjopen-2016-015284
McLaren D., Siemens D.R., Izard J. et al. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome. BJU Int 2008;102(9):1142–6.
DOI: 10.1111/j.1464-410X.2008.07811.x
Cooper C.S., MacIndoe J.H., Perry P.J. et al. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol 1996;156(2 Pt 1):438–41; discussion 441–2.
DOI: 10.1097/00005392-199608000-00028
Gerstenbluth R.E., Maniam P.N., Corty E.W., Seftel A.D. Prostatespecific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002;23(6):922–6.
Morgentaler A., Lipshultz L.I., Bennett R. et al. Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185(4):1256–60.
DOI: 10.1016/j.juro.2010.11.084
Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int 2011;107(9):1369–73.
DOI: 10.1111/j.1464-410X.2011.10193.x
Kacker R., Hult M., San Francisco I.F. et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl 2016;18(1):16–20.
DOI: 10.4103/1008-682X.160270
Kaufman J.M., Graydon R.J. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172(3):920–2.
DOI: 10.1097/01.ju.0000136269.10161.32
Agarwal P.K., Oefelein M.G. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173(2):533–6.
DOI: 10.1097/01.ju.0000143942.55896.64
Mulhall J.P., Trost L.W., Brannigan R.E. et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol 2018;200(2):423–32.
DOI: 10.1016/j.juro.2018.03.115
Salonia A., Bettocchi C., Boeri L. et al. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. Eur Urol 2021;80(3):333–57.
DOI: 10.1016/j.eururo.2021.06.007
Natale C., Carlos C., Hong J. et al. Testosterone therapy after prostate cancer treatment: a review of literature. Sex Med Rev 2021;9(3):393–405.
DOI: 10.1016/j.sxmr.2020.12.003
Pastuszak A.W., Pearlman A.M., Lai W.S. et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013;190(2):639–44.
DOI: 10.1016/j.juro.2013.02.002
Wynia B., Lee T., Taneja S. et al. Testosterone replacement therapy in patients with prostate cancer after prostatectomy: a 5-year single center experience. J Urol 2014;191(4):527.
DOI: 10.1016/j.juro.2014.02.1477
Gray H., Seltzer J., Talbert R.L. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism. Am J Health Syst Pharm 2015;72(7):536–41.
DOI: 10.2146/ajhp140128
Pastuszak A.W., Pearlman A.M., Godoy G. et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013;25(1):24–8.
DOI: 10.1038/ijir.2012.29
Pastuszak A.W., Khanna A., Badhiwala N. et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol 2015;194(5):1271–6.
DOI: 10.1016/j.juro.2015.05.084
Kacker R., Hult M., Conners W., Morgentaler A. Safety of testosterone therapy in men with prostate cancer. J Urol 2014;191(4):e529 –e30.
DOI: 10.1016/j.juro.2014.02.1482"10.1016/j.juro.2014.02.1482
Sarosdy M.F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109(3):536–41.
DOI: 10.1002/cncr.22438
Balbontin F.G., Moreno S.A., Bley E. et al. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int 2014;114(1):125–30.
DOI: 10.1111/bju.12668
Kadomoto S., Shigehara K., Iwamoto H. et al. Testosterone replacement therapy for patients with hypogonadism after high dose-rate brachytherapy for high-risk prostate cancer: a report of six cases and literature review. World J Mens Health 2020;38(1):132–6.
DOI: 10.5534/wjmh.180130
Morales A., Black A.M., Emerson L.E. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009;103(1):62–4.
DOI: 10.1111/j.1464-410X.2008.07882.x
Davila H.H., Arison C.N., Hall M.K. et al. Analysis of the PSA response after testosterone supplemenatation in patients who have previously received management for their localized prostate cancer. J Urol 2008;179(4S):428.
DOI: 10.1016/S0022-5347(08)61255-0
Ory J., Flannigan R., Lundeen C. et al. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol 2016;196(4):1082–9.
DOI: 10.1016/j.juro.2016.04.069
Salonia A., Gallina A., Briganti A. et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer 2011;117(17):3953–62.
DOI: 10.1002/cncr.25985
Yamamoto S., Yonese J., Kawakami S. et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007;52(3):696–701.
DOI: 10.1016/j.eururo.2007.03.052
Lumbiganon S., Patcharatrakul S., Khongcharoensombat W., Sangkum P. Pre- and post-radical prostatectomy testosterone levels in prostate cancer patients. Int J Impot Res 2019;31(2):145–9.
DOI: 10.1038/s41443-019-0116-0
Пушкарь Д.Ю., Роживанов Р.В., Мкртумян А.М. и др. Тестостеронзаместительная терапия в урологической практике. Междисциплинарный подход. Методические рекомендации № 59. Москва, 2019.
Hoffman M.A., DeWolf W.C., Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163(3):824–7.
DOI: 10.1016/S0022-5347(05)67812-3
Ribeiro M., Ruff P., Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997;20(6):605–8.
DOI: 10.1097/00000421-199712000-00015
Sofikerim M., Eskicorapci S., Oruç O., Ozen H. Hormonal predictors of prostate cancer. Urol Int 2007;79(1):13–8.
DOI: 10.1159/000102906
Teloken C., Da Ros C.T., Caraver F. et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005;174(6):2178–80.
DOI: 10.1097/01.ju.0000181818.51977.29
Chuu C.P., Hiipakka R.A., Fukuchi J. et al. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005;65(6):2082–4.
DOI: 10.1158/0008-5472.CAN-04-3992
Chen C.D., Welsbie D.S., Tran C. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33–9.
DOI: 10.1038/nm972
Isaacs J.T., D’Antonio J.M., Chen S. et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate 2012;72(14):1491–1505.
DOI: 10.1002/pros.22504
Schweizer M.T., Antonarakis E.S., Wang H. et al. Effect of bipolar androgen therapy for asymptomatic men with castrationresistant prostate cancer: results from a pilot clinical study. Sci Transl Med 2015;7(269):269ra2.
DOI: 10.1126/scitranslmed.3010563
Schweizer M.T., Wang H., Luber B. et al. Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: results from the phase II BATMAN Study. Prostate 2016;76(13):1218–26.
DOI: 10.1002/pros.23209
Morgentaler A., Caliber M. Safety of testosterone therapy in men with prostate cancer. Expert Opin Drug Saf 2019;18(11):1065–76.
DOI: 10.1080/14740338.2019.1666103